MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002

Contributed by: Business Wire

Logo

Tags

Biotechnology

Other Health

Health

Pharmaceutical

Clinical Trials

MRM Health NV

More Like This

MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)

MRM Health Initiates Clinical Research in Parkinson’s Disease

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors

UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment

Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for U.S. market approval

Professor Dean Fennell, principal investigator, presents results from the Phase 1 MITOPE clinical study of a first-in-human, and potential first-in-class therapeutic, RSO-021. (Photo: Business Wire)

RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC